Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
Published Date: 7/30/2026
Notice
Summary
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
FY2027 VQIP Annual Fee Set
If you are an importer approved to participate in the Voluntary Qualified Importer Program (VQIP), the FY2027 annual user fee is $9,994. The fee is effective August 1, 2026 and remains in effect through September 30, 2027, and it supports VQIP benefits for October 1, 2026 through September 30, 2027.
No Small Business Fee Reduction Offered
FDA is not offering an adjusted (reduced) VQIP fee for small businesses for FY2027. Any future small business fee reduction would require notice-and-comment rulemaking before it could be applied.
Payment Deadlines and Participation Risk
To receive VQIP benefits for the year starting October 1, 2026, approved importers must pay the fee before October 1, 2026; for the first approved year the user fee may not be paid after December 31, 2026. If the fee is not paid before October 1 in a subsequent year, FDA will issue a Notice of Intent to Revoke and will revoke participation if payment is not received within 30 days of that notice.
Payment Methods and Limits Specified
Payments must be in U.S. currency from a U.S. bank and can be made by electronic check (ACH), credit card, or wire transfer via Pay.gov or FDA's User Fees Payment Portal. Credit card payment is available only for balances under $25,000; balances above $25,000 must be paid by ACH or wire transfer.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.
2026-15341, Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (JINADs), and for certain submissions related to JINAD files. This notice establishes the fee rates for FY 2027.
Previous / Next Documents
Previous: 2026-15344, Over-the-Counter Monograph Drug User Fee Rates for Fiscal Year 2027
The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Over-the-Counter Monograph Drug User Fee Amendments (herein referred to as "OMUFA II"), authorizes the Food and Drug Administration (FDA, the Agency, or we) to assess and collect user fees from qualifying manufacturers of over-the-counter (OTC) monograph drugs and submitters of OTC monograph order requests (OMORs) for fiscal years 2026 through 2030. This notice publishes the OMUFA fee rates for fiscal year (FY) 2027.
Next: 2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.